Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration

Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration

Bibliographische Detailangaben
Hauptverfasser:	Chakravarthy, U, Harding, S, Rogers, C, Downes, S, Lotery, A, Wordsworth, S, Reeves, B
Format:	Journal article
Veröffentlicht:	2012

Ähnliche Einträge

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.
von: Chakravarthy, U, et al.
Veröffentlicht: (2012)

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial
von: Chakravarthy, U, et al.
Veröffentlicht: (2012)

Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.
von: Dakin, H, et al.
Veröffentlicht: (2014)

Bevacizumab versus ranibizumab for neovascular age-related macular degeneration:a Meta-analysis
von: Wen-Jie Wang, et al.
Veröffentlicht: (2015-02-01)

Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients
von: Zhe-Li Liu, et al.
Veröffentlicht: (2013-04-01)

Pharmacogenetic Associations with Vascular Endothelial Growth Factor Inhibition in Participants with Neovascular Age-Related Macular Degeneration in the IVAN Study
von: Lotery, A, et al.
Veröffentlicht: (2013)

Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the ivan study
von: Lotery, A, et al.
Veröffentlicht: (2013)

Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration
von: Partha Biswas, et al.
Veröffentlicht: (2011-01-01)

Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
von: David R. Griffin, et al.
Veröffentlicht: (2014-01-01)

A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK
von: Hykin P, et al.
Veröffentlicht: (2016-01-01)

Quality of fixation in eyes with neovascular age-related macular degeneration treated with ranibizumab.
von: Sivaprasad, S, et al.
Veröffentlicht: (2011)

Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab
von: Rachel Hui Fen Lim, et al.
Veröffentlicht: (2017-03-01)

6-weekly bevacizumab versus 4-weekly ranibizumab for neovascular age-related macular degeneration: a 2-year outcome
von: Patrick J Chiam, et al.
Veröffentlicht: (2016-04-01)

Intravitreal Bevacizumab versus Combined Bevacizumab and Triamcinolone Acetonide for Neovascular Age-Related Macular Degeneration
von: Mohammad Riazi-Esfahani, et al.
Veröffentlicht: (2008-12-01)

Short-Term Results of Switch from Conbercept to Bevacizumab or Ranibizumab in Eyes with Persistent Neovascular Age-Related Macular Degeneration
von: Zongyi Wang, et al.
Veröffentlicht: (2020-01-01)

Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?
von: Dimitrios A Karagiannis, et al.
Veröffentlicht: (2009-11-01)

Patient adherence to therapy after switch to aflibercept from bevacizumab or ranibizumab for treatment-refractory neovascular age-related macular degeneration
von: Simon D Archambault, et al.
Veröffentlicht: (2024-01-01)

Efficacy of Intravitreal Bevacizumab in Neovascular Age-Related Macular Degeneration
von: Ariunzaya Altankhuyag, et al.
Veröffentlicht: (2022-12-01)

Treat-And-extend bevacizumab for neovascular age-related macular degeneration: The importance of baseline characteristics
von: Rush, R, et al.
Veröffentlicht: (2014)

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
von: Mohamed A. Hamid, et al.
Veröffentlicht: (2021-04-01)

Machine Learning to Predict Response to Ranibizumab in Neovascular Age-Related Macular Degeneration
von: Andreas Maunz, PhD, et al.
Veröffentlicht: (2023-12-01)

Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
von: Yi-Sheng Chang, et al.
Veröffentlicht: (2018-05-01)

Comparing fixation location and stability in patients with neovascular age-related macular degeneration treated with or without Ranibizumab.
von: Pearce, E, et al.
Veröffentlicht: (2011)

Long-Term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with Ranibizumab
von: Menke, Marcel N., et al.
Veröffentlicht: (2013)

Morphological and functional retinal changes in neovascular age-related macular degeneration treated with intravitreal bevacizumab
von: Deepali R Damkondwar, et al.
Veröffentlicht: (2022-01-01)

The outcomes of aflibercept therapy in patients with age-related macular degeneration resistant to bevacizumab or ranibizumab
von: Erkan Unsal, et al.
Veröffentlicht: (2018-12-01)

Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
von: Scorcia G, et al.
Veröffentlicht: (2010-05-01)

Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
von: Yasuo Yanagi, et al.
Veröffentlicht: (2023-05-01)

Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up
von: Cvetkova NP, et al.
Veröffentlicht: (2016-06-01)

Combination of ranibizumab and indomethacin for neovascular age-related macular degeneration: randomized controlled trial
von: Russo A, et al.
Veröffentlicht: (2018-03-01)

Caregiver Burden in Patients Receiving Ranibizumab Therapy for Neovascular Age Related Macular Degeneration.
von: Rishma Gohil, et al.
Veröffentlicht: (2015-01-01)

Comment on “Assessment of the long-term visual and anatomical outcomes of ranibizumab to treat neovascular age-related macular degeneration”
von: Dan Călugăru, et al.
Veröffentlicht: (2018-11-01)

Fluorescein angiographic characteristic in predominantly classic and occult types of neovascular age-related macular degeneration treated with ranibizumab
von: Cemal Çavdarlı, et al.
Veröffentlicht: (2021-04-01)

Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: Real-world outcomes from the LUMINOUS study.
von: Frank G Holz, et al.
Veröffentlicht: (2020-01-01)

ROLE OF INTRAVITREAL BEVACIZUMAB INJECTION FOR MANAGEMENT OF NEOVASCULAR AGE RELATED MACULAR DEGENERATION
von: Neha K. Desai, et al.
Veröffentlicht: (2016-06-01)

Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study.
von: A M E Schauwvlieghe, et al.
Veröffentlicht: (2016-01-01)

Comparison of bevacizumab and ranibizumab in age-related macular degeneration:a systematic review and meta-analysis
von: Xiao-Yu Zhang, et al.
Veröffentlicht: (2014-04-01)

Anterior uveitis after treatment of age-related macular degeneration with ranibizumab and bevacizumab: uncommon complication
von: Damasceno N, et al.
Veröffentlicht: (2012-07-01)

Predominantly hemorrhagic choroidal neovascular lesion from exsudative age-related macular degeneration treated with intravitreal ranibizumab therapy
von: Miguel Hage Amaro, et al.
Veröffentlicht: (2013-06-01)

Visual Performance in Patients with Neovascular Age-Related Macular Degeneration Undergoing Treatment with Intravitreal Ranibizumab
von: Sarah Sabour-Pickett, et al.
Veröffentlicht: (2013-01-01)